Newsletter Tool

Today's Rundown

Stryker ponies up $3B to buy Vocera and amp up its digital communications
Biogen's Aduhelm faces a key coverage decision next week. Which way will Medicare rule, and how much does it matter?
AMA pans CDC's 'confusing' COVID-19 isolation guidance, calls for negative test requirement
Pfizer, Roche, AstraZeneca and J&J face newly revived lawsuit claiming they funded terrorism in Iraq
With Alnylam in rear view, Maraganore wants to be a biotech multiplier, matchmaker and mentor
Verily links up with Sosei Heptares for GPCR drug discovery
Babylon Health acquires health kiosk company Higi Health in latest effort to scale in U.S. market
Amgen chooses Generate in $1.9B biobucks deal to churn out up to 10 multispecific drugs
With dual approvals, Biohaven's migraine blockbuster-in-waiting snares nearly $500M in 2021
Abbott unveils Lingo line of sports biosensors based on diabetes monitoring tech
Vera Whole Health to merge with healthcare navigation company Castlight Health in $370M deal
Aligos says stop right now to lead hep B med after fruitless phase 1 data

Featured Story

Stryker ponies up $3B to buy Vocera and amp up its digital communications

By Conor Hale

Stryker inked a $3 billion deal to dramatically reshape its digital patient outreach efforts with the acquisition of Vocera Communications.

Biogen's Aduhelm faces a key coverage decision next week. Which way will Medicare rule, and how much does it matter?

By Angus Liu

Amid its sputtering launch, Biogen expects to receive a draft decision on Aduhelm’s coverage on Medicare next week. Industry watchers have been calculating a range of potential scenarios, but whichever direction the ruling goes, doctor feedback suggests it may simply not matter that much.

AMA pans CDC's 'confusing' COVID-19 isolation guidance, calls for negative test requirement

By Dave Muoio

"Physicians are concerned that these recommendations put our patients at risk and could further overwhelm our health care system," wrote AMA President Gerald Harmon, M.D.

Pfizer, Roche, AstraZeneca and J&J face newly revived lawsuit claiming they funded terrorism in Iraq

By Kevin Dunleavy

Pharmaceutical giants Pfizer, AstraZeneca, Roche and Johnson & Johnson will have to answer to charges that they paid bribes to win healthcare contracts in Iraq and in the process funded terrorists who killed Americans during the war. This week, a U.S. appeals court revived a lawsuit that was filed in 2017 and dismissed three years later.

PM Tracker

Featured Story

Stryker ponies up $3B to buy Vocera and amp up its digital communications

Top Stories

Biogen's Aduhelm faces a key coverage decision next week. Which way will Medicare rule, and how much does it matter?

AMA pans CDC's 'confusing' COVID-19 isolation guidance, calls for negative test requirement

Pfizer, Roche, AstraZeneca and J&J face newly revived lawsuit claiming they funded terrorism in Iraq

With Alnylam in rear view, Maraganore wants to be a biotech multiplier, matchmaker and mentor

Verily links up with Sosei Heptares for GPCR drug discovery

Babylon Health acquires health kiosk company Higi Health in latest effort to scale in U.S. market

Amgen chooses Generate in $1.9B biobucks deal to churn out up to 10 multispecific drugs

With dual approvals, Biohaven's migraine blockbuster-in-waiting snares nearly $500M in 2021

Abbott unveils Lingo line of sports biosensors based on diabetes monitoring tech

Vera Whole Health to merge with healthcare navigation company Castlight Health in $370M deal

Aligos says stop right now to lead hep B med after fruitless phase 1 data